Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Total Non-Current Liabilities (2020 - 2024)

Historic Total Non-Current Liabilities for Journey Medical (DERM) over the last 5 years, with Q4 2024 value amounting to $60.2 million.

  • Journey Medical's Total Non-Current Liabilities rose 650.1% to $60.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $60.2 million, marking a year-over-year increase of 650.1%. This contributed to the annual value of $60.2 million for FY2024, which is 650.1% up from last year.
  • Per Journey Medical's latest filing, its Total Non-Current Liabilities stood at $60.2 million for Q4 2024, which was up 650.1% from $56.5 million recorded in Q4 2023.
  • Journey Medical's Total Non-Current Liabilities' 5-year high stood at $96.4 million during Q3 2021, with a 5-year trough of $33.5 million in Q4 2020.
  • In the last 5 years, Journey Medical's Total Non-Current Liabilities had a median value of $74.9 million in 2022 and averaged $70.1 million.
  • Per our database at Business Quant, Journey Medical's Total Non-Current Liabilities soared by 6810.56% in 2022 and then crashed by 3488.35% in 2023.
  • Quarter analysis of 5 years shows Journey Medical's Total Non-Current Liabilities stood at $33.5 million in 2020, then skyrocketed by 54.18% to $51.6 million in 2021, then surged by 68.11% to $86.8 million in 2022, then tumbled by 34.88% to $56.5 million in 2023, then grew by 6.5% to $60.2 million in 2024.
  • Its Total Non-Current Liabilities was $60.2 million in Q4 2024, compared to $56.5 million in Q4 2023 and $68.3 million in Q2 2023.